Trial Profile
A Phase I Dose-Escalation Study of R115777 (Tipifarnib) Plus PS-341 (Bortezomib) in Relapsed or Refractory Acute Leukemias.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Tipifarnib (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 14 Nov 2011 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
- 16 Jun 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov
- 05 Mar 2007 New trial record.